Winrevair, when added to standard of care, reduced clinical worsening events by 76% in adults recently diagnosed with PAH, trial data show.

Stem cell-derived conditioned medium, the liquid that remains after cells are cultured, reduced PAH signs in rats and cells, per a study.

Gossamer Bio has begun the process of acquiring Respira Therapeutics and its lead on-demand PH treatment candidate, RT234.

Columnist Jolie Lizana attended the Pulmonary Hypertension Association's (PHA) PHPN Symposium, which discussed PH research.

As a PH patient and transplant recipient, columnist Anna Jeter relies on her care team when it comes to vaccine recommendations.